# Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

> **NCT00757042** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 78 (actual)

## Conditions studied

- Atopic Dermatitis
- Healthy Volunteers

## Interventions

- **DRUG:** Tezepelumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00757042
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-18
- **Primary completion:** 2011-01-05
- **Final completion:** 2011-01-05
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00757042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00757042, "Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00757042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*